While no approved vaccines target Parkenson's disease (PD), several clinical pathways are being investigated with innovative technologies in 2024.
Different monoclonal antibodies have been investigated as passive immunization, and novel active immunization modalities targeting PD are being studied.
Recently, the findings of a non-peer-reviewed study reveal a significant reduction in PD occurrence following anti-tetanus vaccination, with a time-dependent association between the elapsed time since vaccination and the rate and progression of PD.
Read More
